Inhibikase Therapeutics Q2 EPS $(0.11) Misses $(0.09) Estimate
Benzinga Newsdesk 1 year ago
EarningsEarnings MissesNews
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 83.33 percent increase over losses of $(0.66) per
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 83.33 percent increase over losses of $(0.66) per share from the same period last year.